DENV, dengue virus – Communicable Diseases Research

A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships

Article

Published on 2023-02-012024-09-05
Journal: Antiviral research [Category] update2024,

Where all the Roads Meet? A Crossover Perspective on Host Factors Regulating SARS-CoV-2 infection

Review Article

Published on 2021-12-132023-06-15
Journal: Journal of Molecular Biology [Category] MERS, SARS,

[키워드] ACE2, angiotensin-converting enzyme 2 ALG, Alpha-1,3-glucosyltransferase ARPP-19, cyclic adenosine monophosphate-regulated phosphoprotein 19 BCOR, BCL6 interacting co-repressor C1QTNF7, C1q and tumor necrosis factor-related protein 7 CDG1C, congenital disorder of N-linked glycosylation type 1C CDGS, carbohydrate-deficient glycoprotein syndrome CHIKV, Chikungunya virus CIRV, Carnation Italian ringspot virus COG, conserved oligomeric Golgi COVID-19 COVID-19, coronavirus disease 19 CRISPR CSNK2B, casein kinase 2 subunit beta CTRP, C1q complement/TNF-related protein DDX, DEAD-box RNA helicase DENV, dengue virus EBV, Epstein–Barr virus EPLIN, epithelial protein lost in neoplasm GDI2, GDP dissociation inhibitor beta HCC, hepatocellular carcinoma HCV, hepatitis C virus HDACS, histone deacetylases HIV-1, human immunodeficiency virus 1 host factors HPV, Human Papilloma Virus HSV-1, Herpes Simplex Virus-1 IAV, influenza A virus LIMA-1, LIM domain and actin binding-1 LRRN2, leucine-rich repeat neuronal protein 2 PP2A, Protein phosphatase 2A RRA, robust-rank aggregation RSV, respiratory syncytial virus SARS-CoV-2 SBV, Schmallenberg virus SLC35B2, solute carrier family 35 member B2 SNPs, single nucleotide polymorphisms SREBP3, sterol regulatory element binding protein 3 TBSV, Tomato bushy stunt virus TLR, toll-like receptors TMPRSS2, Transmembrane Protease Serine 2 TMV, Tobacco Mosaic Virus VACV, vaccinia virus Viral diseases VPS, vacuolar protein sorting VSV, Vesicular Somatitis Virus
[DOI] 10.1016/j.jmb.2021.167403 PMC 바로가기 [Article Type] Review Article

SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies

Review

Published on 2021-10-162022-10-04
Journal: International immunopharmacology [Category] MERS, SARS, 변종, 신약개발, 유전자 메커니즘,

[키워드] Abstract ACE-2, Angiotensin-converting enzyme 2 AKI, acute kidney injury Ang II, Angiotensin II BALF, Broncho alveolar lavage fluid cGMP, Good Manufacturing Practice Characteristics coronavirus disease 19 COVID-19 COVID-19 infection COVID-19, Coronavirus disease of 2019 CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats CRS, Cytokine release syndrome CT, Computed tomography CT, Cycle threshold current Cytokine storm DENV, dengue virus develop diagnostic tests dimension drugs emerging variants FDA, Food and Drug Administration FNR, False‐negative rate Genome GGOs, Ground-glass opacities global effort HAT, Human airway trypsin-like protease health emergency Health Organization HIV, Human immunodeficiency virus IBV, infectious bronchitis virus ICU, Intensive care unit IL, interleukin immune response immune responses Immunity include Infection International JEV, Japanese encephalitis virus lack LAMP, Loop-mediated isothermal amplification LF, Lactoferrin mechanism MIP1α, Macrophage inflammatory protein 1α MRI, Magnetic resonance imaging MSC, Mesenchymal Stem Cells Mutation mutations NCD, Newcastle disease virus new virus NP, nasopharyngeal NSPs, Nonstructural proteins OP, Oropharyngeal pandemic Pathogenesis pathogenicity Potential treatment Prevent problem RAS, Renin-angiotensin system RBD, Receptor binding-domain RdRp, RNA-dependent RNA polymerases Reinfection Research resulting SARS-CoV SARS-CoV-2 SARS-COV-2, severe acute respiratory syndrome coronavirus-2 severity TGF, Transforming growth factor Th17, T helper 17 the disease the SARS-CoV-2 therapeutic therapy Transmissibility treat Vaccine vaccine candidate Vaccine development Vaccines variant variants variants of SARS-CoV-2 virus VLPs, Virus-like particles VTM, Viral transport medium while WHO WNV, West Nile virus
[DOI] 10.1016/j.intimp.2021.108232 PMC 바로가기 [Article Type] Review

Neutrophils at the crossroads of acute viral infections and severity

Article

Published on 2021-07-182023-06-15
Journal: Molecular aspects of medicine [Category] MERS, SARS,

Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets

Review

Published on 2021-04-262023-06-15
Journal: Progress in lipid research [Category] MERS, SARS,

[키워드] ACE2, angiotensin converting enzyme 2 BPs, bisphosphonates cholesterol CMV, human cytomegalovirus CoV, coronavirus DENV, dengue virus EBOV, Ebola virus FDPS, farnesyl diphosphate synthase HCV, hepatitis C virus HDL, high-density lipoprotein HIV, Human immunodeficiency virus HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase IAV, influenza A virus IFN, interferon IL, interleukin KSHV, Kaposi's sarcoma-associated herpesvirus LDL, low-density lipoprotein lipid homeostasis LXR, liver X receptor MβCD, methyl-β-cyclodextrin MERS, middle-East respiratory syndrome Mevalonate pathway inhibitors Mpro, SARS-CoV-2 main protease MVA, mevalonate PI, phosphatidil-inositol RSV, respiratory syncytial virus SARS-CoV-2 SARS, Severe acute respiratory syndrome SREBP, sterol regulatory element binding protein statins T_reg, T regulatory cells TMPRSS2, Transmembrane Protease Serine 2 viral infections VZV, Varicella zoster virus WNV, West Nile virus ZIKV, Zika virus
[DOI] 10.1016/j.plipres.2021.101099 PMC 바로가기 [Article Type] Review

Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus

글루코실세라마이드 합성효소 억제제는 SARS-CoV-2 및 인플루엔자 바이러스의 복제를 방지합니다

Accelerated Communication

Published on 2021-02-252022-09-10
Journal: The Journal of Biological Chemistry [Category] 비임상, 신종인플루엔자,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analogue antiviral drugs Antiviral effect antiviral therapies breath caused CC50, cytotoxicity concentration 50% cell membranes Cerdelga clinical trials component coronavirus COVID-19 COVID-19 pandemic CPE, cytopathic effect creating cross DENV, dengue virus dependency disrupt DMSO, dimethyl sulfoxide DNJ, deoxynojirimycin drug Drug administration DsiRNA, Dicer-substrate siRNA examined food GCS, glucosylceramide synthase GlcCer, glucosylceramide global health glucosylceramide glucosylceramide synthase GZ-161, GENZ-667161 GZ-346, Genz-123346 H1N1 Health host cell host cell membrane host cell membranes Infection Influenza Influenza virus inhibit inhibitor life cycle life cycles limit LSD, lysosomal storage disease MDCK, Madin–Darby Canine Kidney membrane MOI, multiplicity of infection NB-DNJ, N-butyl–DNJ not applicable outcomes Phase III clinical trials PR8, influenza virus A/PR/8/34 (H1N1) Prevent Replication replication of SARS-CoV-2 respiratory SARS-CoV-2 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 severe acute respiratory syndrome Coronavirus SI, selective index specific inhibitor specific inhibitors sphingolipids Support synthesis the United State therapeutic target Treatment United States Vaccine venglustat Viral viral life cycle virus viruses
[DOI] 10.1016/j.jbc.2021.100470 PMC 바로가기 [Article Type] Accelerated Communication

Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19

Article

Published on 2020-12-262023-06-14
Journal: Journal of molecular and cellular cardiology [Category] MERS, SARS,

[키워드] AC, Anticoagulation ACE2, angiotensin-converting enzyme 2 AngI, Angiotensin I ARB, AngII-type I receptor blockers ARDS, acute respiratory distress syndrome AT1R, angiotensin II type 1 receptor BNP, B-type natriuretic peptide Clinical features CMRI, Cardiovascular magnetic resonance COVID-19 COVID-19, Coronavirus disease 2019 CRP, C-reactive protein CT, Computed tomography CTD, C-terminal domain DENV, dengue virus DIC, disseminated intravascular coagulation DPP4, Dipeptidyl peptidase IV EC, Endothelial cells ECG, electrocardiogram ECMO, extracorporeal membrane oxygenation FDA, Food and Drug Administration GGO, Ground-glass opacities HCoV, human coronavirus HIV, Human immunodeficiency virus infection ICU, Intensive care unit IFN, interferon IGG, immunoglobulin g IL, interleukin JAK2, Janus kinase 2 JEV, Japanese encephalitis virus LV, Left ventricle LVEF, Left ventricular ejection fraction MERS-CoV, Middle East respiratory syndrome-coronavirus MRA, Mineralocorticoid receptor antagonists MRI, Magnetic resonance imaging NTD, N-terminal domain PAR-1, Proteinase-activated receptor 1 PE, Pulmonary embolism PEEP, positive end-expiratory pressure physiopathology PKC, Protein kinase C RAS, Renin-angiotensin system RBD, receptor-binding domain RBM, receptor-binding motif RDV, Remdesivir RV, Right ventricle S-protein, Spike protein SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 SARS-CoV, severe acute respiratory syndrome coronavirus STAT3, Signal transducer and activators of transcription 3 STEMI, ST-segment elevated myocardial infarction TMPRSS2, Transmembrane serine protease 2 TNF, Tumor Necrosis Factor Treatment TTC, Takotsubo cardiomyopathy TTE, Transthoracic echocardiography vWF, von Willebrand factor WHO, World Health Organization
[DOI] 10.1016/j.yjmcc.2020.12.009 PMC 바로가기 [Article Type] Article

ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis

Review Article

Published on 2020-08-202023-06-16
Journal: Cytokine [Category] MERS,